Pancreatic Cancer clinical trials in Arkansas

11 actively recruiting pancreatic cancer trials at 11 sites across Arkansas.

Data from ClinicalTrials.gov · last refreshed 2026-04-20

Phase 3 Recruiting Academic/Other

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

This phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-6 months of chemotherapy. Usual care …

Sponsor: NRG Oncology

NCT ID: NCT06958328

Sites in Arkansas:

NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas

View on ClinicalTrials.gov →

Phase 2, Phase 3 Recruiting Industry

A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

The purpose of this study is to assess the safety and efficacy of BMS-986504, a selective, MTA-cooperative PRMT5 inhibitor, in combination with Nab-paclitaxel/Gemcitabine (nab-p/gem) versus placebo in combination with nab-p/gem, in partici…

Sponsor: Bristol-Myers Squibb

NCT ID: NCT07076121

Sites in Arkansas:

Highlands Oncology Group — Springdale, Arkansas

View on ClinicalTrials.gov →

Phase 2, Phase 3 Recruiting Industry

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

Study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and metastatic pancreatic ducta…

Sponsor: Pfizer

NCT ID: NCT06989437

Sites in Arkansas:

Central Arkansas Radiation Therapy Institute, dba CARTI — Bryant, Arkansas
Central Arkansas Radiation Therapy Institute, dba CARTI — Conway, Arkansas
CARTI Cancer Center — Little Rock, Arkansas
Central Arkansas Radiation Therapy Institute, dba CARTI — North Little Rock, Arkansas
Central Arkansas Radiation Therapy Institute, dba CARTI — Pine Bluff, Arkansas

View on ClinicalTrials.gov →

Phase 2, Phase 3 Recruiting Industry

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcino…

Sponsor: Panbela Therapeutics, Inc.

NCT ID: NCT05254171

Sites in Arkansas:

Genesis Cancer and Blood Institute (SCRI) — Hot Springs, Arkansas

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT04858334

Sites in Arkansas:

Mercy Hospital Fort Smith — Fort Smith, Arkansas
CHI Saint Vincent Cancer Center Hot Springs — Hot Springs, Arkansas
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas

View on ClinicalTrials.gov →

Phase 2 Recruiting Network

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work…

Sponsor: SWOG Cancer Research Network

NCT ID: NCT05040360

Sites in Arkansas:

Mercy Hospital Fort Smith — Fort Smith, Arkansas
CARTI Cancer Center — Little Rock, Arkansas

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Industry

Study of LP-184 in Patients With Advanced Solid Tumors

The primary objective of this study is to evaluate the safety, tolerability, MTD and RP2D of LP-184 in patients with advanced solid tumors who have relapsed from or are refractory to standard therapy or for whom no standard therapy is avai…

Sponsor: Lantern Pharma Inc.

NCT ID: NCT05933265

Sites in Arkansas:

Highlands Oncology Group — Springdale, Arkansas

View on ClinicalTrials.gov →

Phase 1 Recruiting Industry

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out wh…

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

NCT ID: NCT04389632

Sites in Arkansas:

Highlands Oncology Group — Fayetteville, Arkansas
Highlands Oncology Group — Rogers, Arkansas
Highlands Oncology Group — Springdale, Arkansas

View on ClinicalTrials.gov →

Phase 1 Recruiting Industry

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose. This study is seeking participants who have…

Sponsor: Pfizer

NCT ID: NCT06447662

Sites in Arkansas:

Highlands Oncology Group, PA — Fayetteville, Arkansas
Highlands Oncology Group, PA — Rogers, Arkansas
Highlands Oncology Group — Springdale, Arkansas

View on ClinicalTrials.gov →

Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT05334069

Sites in Arkansas:

Mercy Hospital Fort Smith — Fort Smith, Arkansas
CARTI Cancer Center — Little Rock, Arkansas

View on ClinicalTrials.gov →

Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.

NCT ID: NCT03452774

Sites in Arkansas:

Massive Bio SYNERGY-AI site — Little Rock, Arkansas

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20